sur Bausch Health Companies Inc. (NASDAQ:BHC)
Bausch Health Decides Against Sale of Bausch + Lomb
Bausch Health Companies Inc. announced that it will not proceed with the sale of its subsidiary, Bausch + Lomb Corporation. The decision follows a review of a private equity firm's proposal, which was deemed not reflective of Bausch + Lomb's long-term potential. Consequently, Bausch Health will retain its 88% interest in the subsidiary.
In 2024, Bausch Health sought advice on liability management and engaged with Bausch + Lomb concerning the company's separation. Despite interest in a complete separation, the boards opted not to pursue the sale. Bausch Health plans to explore other liability management strategies, including new debt financing.
The company remains focused on enhancing business performance, reflected by adjustments in its 2024 revenue and earnings guidance. Bausch Health will release its full 2024 financial results and 2025 guidance on February 19, 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Bausch Health Companies Inc.